side-area-logo

About Eloxx

Committed to Treating Rare and
Ultra-Rare Genetic Diseases

Eloxx Pharmaceuticals is a clinical stage company developing first in class therapeutics for the treatment of genetic disease caused by non-sense mutations.

The company is led by a management team experienced in the development of rare disease therapeutics. All of us at Eloxx share the same goal: to bring safe and effective therapies to the children and adults suffering from genetic diseases who need them, as quickly as possible

Management

Mr. Robert (Bob) E. Ward is the Chairman of the Board and Chief Executive Officer of Eloxx Pharmaceuticals, Inc. (“Eloxx”). He previously served as the Chief Executive Officer and President at Radius Health, Inc. (NASDAQ: RDUS) successfully completing the initial public offering that became the top performing IPO; raised over $780M from private and public sources; achieved FDA approval and launch of the new drug TYMLOStm injection while gaining Fast Track development status for the Elacestrant oncology program. Prior to joining Radius, Mr. Ward held a series of progressive management and executive roles with established companies such as NPS Pharmaceuticals, Schering-Plough (Merck), Pharmacia (Pfizer), Bristol-Myers Squibb and Genentech. Mr. Ward has been a Director of Akari Therapeutics, Plc since October 14, 2016 where he chairs the Governance Committee. He served as a Director of Radius from December 2013 until July 16, 2017. Mr. Ward serves as a Director of the Massachusetts High Technology Council. Mr. Ward received a B.A. in Biology and a B.S. in Physiological Psychology, both from the University of California, Santa Barbara, an M.S. in Management from the New Jersey Institute of Technology and an M.A. in Immunology from the John Hopkins University School of Medicine.

Dr. Huertas has been active in the pharmaceutical industry for nearly 20 years and is experienced in research, development, medical affairs, and regulatory affairs concerning therapeutics for human genetic and metabolic diseases. Dr. Huertas’ last position was with Precision Medicine as Clinical Lead and Head of Precision Medicine for Rare Diseases at Pfizer Worldwide Research & Development. Dr. Huertas has extensive experience dealing with and participating in negotiations with regulatory authorities in the US (FDA), EU (EMA), Japan (PMDA), and throughout Latin America. He led the clinical team that filed for approval of and registered Fabrazyme (agalsidase beta) in the United States, Europe, and Japan. Dr. Huertas is a graduate of Stanford University (MS, Biochemistry), Harvard University (PhD, Cell and Developmental Biology), the Program in Health Sciences and Technology between Harvard Medical School and the Massachusetts Institute of Technology (MD), and the Sloan School of Management at the Massachusetts Institute of Technology (MS, Management). He trained in Internal Medicine, Rheumatology, and Palliative Care at Massachusetts General Hospital.

Dr. Huertas has been active in the pharmaceutical industry for nearly 20 years and is experienced in research, development, medical affairs, and regulatory affairs concerning therapeutics for human genetic and metabolic diseases. Dr. Huertas’ last position was with Precision Medicine as Clinical Lead and Head of Precision Medicine for Rare Diseases at Pfizer Worldwide Research & Development. Dr. Huertas has extensive experience dealing with and participating in negotiations with regulatory authorities in the US (FDA), EU (EMA), Japan (PMDA), and throughout Latin America. He led the clinical team that filed for approval of and registered Fabrazyme (agalsidase beta) in the United States, Europe, and Japan. Dr. Huertas is a graduate of Stanford University (MS, Biochemistry), Harvard University (PhD, Cell and Developmental Biology), the Program in Health Sciences and Technology between Harvard Medical School and the Massachusetts Institute of Technology (MD), and the Sloan School of Management at the Massachusetts Institute of Technology (MS, Management). He trained in Internal Medicine, Rheumatology, and Palliative Care at Massachusetts General Hospital.

Mr. Weaver is a seasoned financial executive with more than 30 years of experience in leading business and financial operations for private and public companies, including financing transactions, strategic planning, investor relations, and business development initiatives. Mr. Weaver has been instrumental in raising more than $900 million in private and public equity and debt financing for both U.S. and international life science companies. Prior to joining Eloxx, Mr. Weaver served as Chief Financial Officer of Prometic Life Sciences, where he led the Company’s global financial team. Previously, Mr. Weaver served as Executive Vice President and Chief Financial Officer of Oryzon Genomics where he managed the Company’s IPO financing. Earlier in his career, Mr. Weaver served as Chief Financial Officer of several other life sciences companies, including Fibrocell Science, Celsion Corp., Poniard Pharmaceuticals, and Sirna Therapeutics. In addition, Mr. Weaver currently serves as a member of the Board of Directors of Egalet Corporation and Atossa Genetics. Mr. Weaver received his M.B.A. from Boston College, a B.S. in accounting from Trinity University, and U.S. CPA certification.

Dr. Sharpe brings with him > 25-years of experience in leading preclinical safety and drug discovery and development in pharmaceutical companies. Previously, Dr. Sharpe served as Senior Director Preclinical Safety and Operations at Anavex Life Sciences (NASDAQ: AVXL), a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of Alzheimer’s disease, other central nervous system diseases, pain, and various cancers. In this position, he was leading the efforts of toxicology, preclinical program development and planning and study monitoring. In parallel, he consulted on these topics for small to midsize biotech and pharmaceutical companies. Prior to joining Anavex, Dr. Sharpe served as Acting Head and Program Director for ALS disease area group at Biogen, Inc (NASDAQ: BIIB), a global biotechnology company specializing in the discovery, development, and delivery of therapies for the treatment of neurodegenerative diseases. Before joining Biogen, Dr. Sharpe was leading multiple global integration projects for the Schering-Plough/Organon and Merck for >20 years. During that period, he was leading toxicology aspects for oligonucleotide, small and large molecule development programs, developed and implemented new outsourcing strategy for Preclinical Safety Group and served as a member of Global Preclinical Safety Senior Staffs, in which he was responsible for managing all scientific, resource, compliance, and operational issues. Dr. Sharpe holds Ph.D. in Neuroscience from the Rutgers, State University Of New Jersey, NJ, and M.A. and B.Sc. in Biology/Physiology and Biology, respectfully, from the William Paterson University, Wayne, NJ. He is the co-author of multiple peer-review papers/abstracts, and also a member in Society of Neuroscience (from 1991), American Association For the Advancement of Scientist (from 1992), Society of Toxicology and Roundtable of Toxicology Consultants (from 2015).

Dr. van Duzer is a senior pharmaceutical industry executive with approx. 30-years of experience in medicinal chemistry research, chemical development programs and GMP manufacturing to support IND filing and clinical trials. In addition, he is the inventor of both Ricolinostat (ACY-1215) and Citarinostat (ACY-241), Selective HDAC 6 inhibitors, currently being developed for the treatment of Multiple Myeloma. In his last position, Dr. van Duzer served as the VP of Chemistry and Manufacturing at Acetylon Pharmaceuticals, in which he was leading outsourced GMP manufacturing for both drug substance API and drug product as well as the medicinal chemistry research and chemical development programs. Dr. van Duzer received his PhD and MSc in synthetic organic chemistry from Yale University, US and BSc (with honors) in chemistry from University of Pennsylvania, Philadelphia, PA. He is the co-inventor of 36 patents and co-authored 18 peer-reviewed scientific papers.

Dr. Pelled brings to Eloxx over 15 years of experience in the biotech industry. Prior to joining Eloxx, he headed the preclinical research and development at Chiasma Pharmaceuticals Ltd. (NASDAQ:CHMA), a drug company that redevelops poorly-absorbed small molecules into oral drugs, and at NiTi Surgical Solutions, a medical device company that focused on implants for gastrointestinal surgery. Prior to NiTi, he was responsible for clinical research and for the developing of new molecules in the medical food company, Enzymotec (NASDAQ:ENZY), where he served as the Director of Clinical Studies and as the CTO. Dr. Pelled has published over 25 original papers in peer-reviewed journals and he holds 15 patents. He received his PhD in Biochemistry from the Weizmann Institute of Science, and obtained BSc and MSc degrees in Chemistry and Clinical Biochemistry from the Tel-Aviv University.

Board of Directors

Mr. Robert (Bob) E. Ward is the Chairman of the Board and Chief Executive Officer of Eloxx Pharmaceuticals, Inc. (“Eloxx”). He previously served as the Chief Executive Officer and President at Radius Health, Inc. (NASDAQ: RDUS) successfully completing the initial public offering that became the top performing IPO; raised over $780M from private and public sources; achieved FDA approval and launch of the new drug TYMLOStm injection while gaining Fast Track development status for the Elacestrant oncology program. Prior to joining Radius, Mr. Ward held a series of progressive management and executive roles with established companies such as NPS Pharmaceuticals, Schering-Plough (Merck), Pharmacia (Pfizer), Bristol-Myers Squibb and Genentech. Mr. Ward has been a Director of Akari Therapeutics, Plc since October 14, 2016 where he chairs the Governance Committee. He served as a Director of Radius from December 2013 until July 16, 2017. Mr. Ward serves as a Director of the Massachusetts High Technology Council. Mr. Ward received a B.A. in Biology and a B.S. in Physiological Psychology, both from the University of California, Santa Barbara, an M.S. in Management from the New Jersey Institute of Technology and an M.A. in Immunology from the John Hopkins University School of Medicine.

Dr. Silvia Noiman has over 20 years of experience as an entrepreneur and executive in the biopharmaceuticals industry, including serving as venture partner at Pontifax Venture Capital. Dr. Noiman founded and served as Executive Chairwoman of many of the Pontifax VC portfolio companies, including cCAM Biotherapeutics Ltd, acquired by Merck (NYSE:MRK) in 2015 and Quiet Therapeutics Ltd. She was also founder and Senior Vice President of Predix Pharmaceuticals Ltd., bringing a small early-stage drug discovery company from inception to a $500M publicly traded multi-product company (NASDAQ, EPIX). Under Dr. Noiman’s leadership, the company progressed four discovery programs to late stage clinical trials and formed significant big pharma partnerships. Prior to founding Predix, she was engaged in large-scale entrepreneurial activities in the biotech industry in Israel. Dr. Noiman holds a PhD in Molecular Biology from Tel Aviv University and did a post-doc at the Weizmann Institute of Science. Dr. Noiman has published numerous papers and holds several patents.

Mr. Veinrib has extensive managerial experience in the internet, digital, and communication fields. He worked as a VP at Elron, as well as serving as Executive Assistant to the President and CEO at Discount Investment Corporation (DIC). Mr. Veinrib previously served as director of NetVision and Nana10 as well as other companies within the DIC group. Mr. Veinrib holds a B.A. in Economics from Tel Aviv University.

Mr. Nussbaum is a managing partner and the co-founder of The Pontifax Group, which established 3 funds with over $220 million under management and over 30 portfolio companies. Over the past 10 years’, Mr. Nussbaum has been managing The Pontifax Group’s activity together with Tomer Kariv. From 2006 to 2008 he also served as CEO of Biomedix Ltd. and Spearhead Ltd., and was Chairman of the Board of Nasvax Ltd. Mr. Nussbaum’s experience in the life sciences arena coupled with 10 years’ experience in the business intelligence field create a unique blend of skills, enabling him to support companies from inception to commercialization. Mr. Nussbaum also serves on the Boards of Directors of many of The Pontifax Group’s portfolio companies, including Kite Pharma Inc. (public co.), Insuline Ltd. (public co.), BioBlast (public co.), UroGen Pharma (formerly, TheraCoat; public co.), CollPlant (public), ProTab, Quiet, and Fusimab Ltd, and as Ocon Chairman of the Board.

Tomer is the co-founder and Chief Executive Officer of Pontifax – The fund is running more than 45 portfolio companies around the globe and serves as an active board member of many of the funds’ portfolio companies, assuming a special responsibility for strategic planning. Among other positions, Tomer serves as the Chairman of Check-Cap and is a board member at Macrocure and V-Wave. During the 10 years prior to establishing Pontifax, he held senior management positions at top Israeli financial institutions, playing a key role in investing in, nurturing and managing technology driven startups. Tomer holds a B.A. in Economics from Harvard University and a J.D. from Harvard Law School.

Mr. Rubin joined Eloxx board of directors on 2017 and formerly served on the board of directors of Sevion Therapeutics, Inc. (OTCBB:SVON). He served as Executive Vice President – Administration and as a director of OPKO Health, Inc. (NASDAQ: OPK) since 2007. Mr. Rubin currently serves on the board of directors of VBI Vaccines, Inc. (NASDAQ:VBIV), a commercial-stage biopharmaceutical which develops, produces and markets next generation of vaccines to address unmet needs in infectious disease and immuno-oncology, Cogint, Inc. (NASDAQ MKT: COGT), an information solutions provider focused on the data-fusion market, Kidville, Inc. (OTCBB:KVIL), which operates large, upscale facilities, catering to newborns through five-year-old children and their families and offers a wide range of developmental classes for newborns to five-year-olds, Non-Invasive Monitoring Systems, Inc. (OTCBB:NIMU), a medical device company, Cocrystal Pharma, Inc. (OTCBB: COCP), a publicly traded biotechnology company developing new treatments for viral diseases, Castle Brands, Inc. (NYSE MKT:ROX), a developer and marketer of premium brand spirits, Neovasc, Inc. (TSXV:NVC), a company developing and marketing medical specialty vascular devices, and ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products. Mr. Rubin previously served as a director of Dreams, Inc. (NYSE MKT: DRJ), a vertically integrated sports licensing and products company, Safestitch Medical, Inc. prior to its merger with TransEnterix, Inc., SciVac Therapeutics, Inc. prior to its merger with VBI Vaccines, Inc., Tiger X Medical, Inc. prior to its merger with BioCardia, Inc., and PROLOR Biotech, Inc., prior to its acquisition by the Company in August 2013. Mr. Rubin served as the Senior Vice President, General Counsel and Secretary of IVAX from August 2001 until September 2006.

Dr. Zafi Avnur joined Eloxx board of directors on June 2017. Dr. Avnur is the Chief Scientific officer at Quark Venture Inc, a venture investment fund focused on life sciences investments. Prior to Quark, Dr. Avnur was the Global Head of Academic Innovation, Roche Partnering 2009 – 2016. She was responsible for creating relationships with the world’s leading academic institutions and world class innovators, gaining Roche early access to innovation. She has created nine startup companies. Dr. Avnur was also named Global Head of Neglected Diseases Roche Partnering 2010-2012. Preceding her academic innovation leadership role, Dr. Avnur assumed responsibility for scientific evaluations of partnering opportunities and started the “Finder” group for Biomarkers for all therapeutic areas at Roche. She acted as Liaison between Pharma and Diagnostic Divisions and contributed to the PHC (Personalized Health Care) initiative. Prior to her partnering roles, Dr. Avnur worked in diagnostics and pharmaceuticals research and development for nearly 20 years. She held number positions progressing from scientist and manager to global responsibilities. In this role she was overseeing the advancement of compounds from the bench into the clinic, and was involved in the design and execution of early clinical studies that characterize the pharmacodynamics and clinical effects of a number of compounds. In her management roles, Dr. Avnur ran groups of up to 44 scientists. Dr. Avnur was named Distinguished Scientist, the highest scientific appointment at Roche. Major scientific achievements include advancing three compounds (a PTHrP analog and two vitamin D analogs, for the treatment of postmenopausal osteoporosis) from early exploratory discovery research to the clinic.

Martijn Kleijwegt joined Eloxx board of directors on June 2017. He founded LSP, one of Europe’s largest and most experienced healthcare investment firms, in 1998 and is currently a Managing Partner and co-owner of the firm. His prime focus and responsibility within LSP is to invest in unlisted securities and the general management of the firm. Prior to establishing LSP, Martijn ran another investment firm where he was responsible for investments in the healthcare sector. As one of Europe’s most experienced healthcare investors, Martijn brings over 30 years of hands-on finance and investment experience to the LSP team. He has also been appointed a Director of a large number of companies, all of which he helped to grow and flourish. Among others, Martijn currently serves as a Director of Prosensa, a company that aims to find a cure for Duchenne Muscular Dystrophy, a rare muscle disease for which there is presently no treatment.